Heparin-induced thrombocytopenia

HIT is a serious immune-mediated reaction to heparin, a commonly used blood-thinning medication, in which antibodies form that activate platelets, causing both a drop in platelet count and, paradoxically, an increased risk of dangerous blood clots. It typically develops five to ten days after starting heparin. Recognising HIT promptly is important because continuing heparin in this situation is dangerous.

HIT is caused by the immune system forming antibodies against a complex of heparin and a platelet protein called platelet factor 4, which then abnormally activates platelets. It can occur with standard heparin or, less often, with low molecular weight heparin. Previous heparin exposure can lead to a faster reaction if heparin is used again.

The characteristic finding is a significant drop in platelet count during or shortly after heparin treatment, sometimes with new blood clots forming in unusual sites, skin reactions at injection sites, or a sudden reaction after an intravenous dose. Many cases are first identified through routine platelet monitoring rather than obvious clinical symptoms. Any unexpected clot occurring during heparin treatment should raise suspicion for HIT.

Yes, despite the low platelet count, HIT carries a significant risk of serious blood clots, including deep vein thrombosis, pulmonary embolism, or stroke, making it a paradoxical and potentially life-threatening condition. Prompt treatment substantially reduces this risk. It requires urgent recognition and action rather than routine monitoring alone.

Treatment involves immediately stopping all sources of heparin and starting an alternative non-heparin anticoagulant to manage clotting risk while the reaction resolves. Platelet transfusions are generally avoided unless there is significant bleeding, since they do not address the underlying mechanism. Close monitoring continues until platelet counts recover and clotting risk normalises.

Using low molecular weight heparin rather than unfractionated heparin where clinically appropriate reduces, though does not eliminate, the risk, alongside using heparin only when necessary and monitoring platelet counts regularly during treatment. A documented history of previous HIT is an important factor considered before any future heparin use. Awareness among clinical teams of the risk supports early detection if HIT does develop.

Many conditions and medications can cause low platelet counts without the paradoxical clotting risk seen specifically in HIT. HIT is suspected based on the specific timing relative to heparin exposure and the pattern of platelet drop, and can be confirmed with specific antibody blood tests. This distinction is clinically important because the correct treatment, stopping heparin and starting an alternative anticoagulant, differs from management of low platelets due to other causes.

HIT should be urgently considered in anyone on or recently exposed to heparin who develops a significant platelet drop, particularly with a new blood clot, requiring immediate hospital assessment and action. This is not something to manage with routine or delayed follow-up given the risk of serious clotting complications. Anyone with a known previous history of HIT should ensure this is clearly flagged in their medical records for future reference.